Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)

Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)

The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting. A multicenter retrospec...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine and metabolic science Vol. 15; p. 100164
Main Authors: Jammah, Anwar, Roushdy, Nagwa, Gamil, Mohamed, Diab, Nidal Abu, Abdelmonaem, Naglaa, Safarini, Saher, Gadallah, Mohamed, Zaid, Nedal Abu, Shihadeh, Yahya, Saeed, Mohamed, Sadik, Jamaa, Akil, Yasser
Format: Journal Article
Language:English
Published: Elsevier Ltd 30-06-2024
Elsevier
Subjects:
Glargine
iGlarLixi
Insulin
Lixisenatide
Type-2 diabetes mellitus
GLP-1 RAs
RWE
T2DM
KM
Type-2 diabetes mellitus
OADs
T1D
STROBE
HRU
IDF
IQR
Insulin
Lixisenatide
AEs
MENA
SUs
FRC
RCTs
iGlarLixi
FPG
HbA1c
Glargine
BMI
ED
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting. A multicenter retrospective non-comparative study was conducted on 224 people with T2DM on Oral anti-diabetics (OADs) or in combination with basal insulin who initiated treatment with iGlarLixi in Saudi Arabia. Data of at least 180 days (± 30 days) before and after initiating iGlarLixi were retrieved. Mean HbA1c significantly decreased after iGlarLixi start, with a mean reduction of 1.6% at six months. The mean reduction in the FPG was −38.8 (95% CI -46.5 to −31.1, p < 0.001). The weight dropped from 86.17 kg to 83.33 kg after 6 months post-iGlarLixi initiation [mean reduction = −2.86, P < 0.001]. The incidence of reported hypoglycemia, symptomatic documented and/or severe cases, decreased from 0.513 (95% CI 0.33 to 0.76) per person-year at baseline to 0.002 (95% CI 0.001 to 0.011) six months after iGlarLixi. iGlarLixi is effective and well tolerated for improved glycemic control in patients with advanced therapy from OADs or insulin in Saudi Arabia. •Significant glycemic control was observed in patients over 60 years old and those using DPP-IV Inhibitors.•A significant reduction in mean HbA1c was achieved after iGlarLixi start at six months, in previously controlled patients with T2D.•iGlarLixi was well tolerated and caused a remarkable reduction in weight after six months of use.
ISSN:2666-3961
2666-3961
DOI:10.1016/j.endmts.2024.100164